SK Capital is set to acquire Canadian generics giant Apotex, with the private investment firm promising “support Apotex’s next phase of growth and continued innovation for patient affordability.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?